2019
DOI: 10.1016/j.wneu.2019.01.039
|View full text |Cite
|
Sign up to set email alerts
|

Incidence of Dural Venous Sinus Thrombosis in Patients with Glioblastoma and Its Implications

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4

Citation Types

0
10
0

Year Published

2019
2019
2023
2023

Publication Types

Select...
4
2

Relationship

0
6

Authors

Journals

citations
Cited by 9 publications
(10 citation statements)
references
References 43 publications
0
10
0
Order By: Relevance
“…No such cases have reported the occurrence of CVST directly attributable to temozolomide. However, there is one study reporting CVST in a patient with a brain tumor treated with temozolomide, focal brain radiotherapy plus bevacizumab where the possible risk of thrombosis was attributed to the anti-angiogenic agent [3]. Our patient did not receive bevacizumab therapy.…”
Section: Discussionmentioning
confidence: 77%
See 4 more Smart Citations
“…No such cases have reported the occurrence of CVST directly attributable to temozolomide. However, there is one study reporting CVST in a patient with a brain tumor treated with temozolomide, focal brain radiotherapy plus bevacizumab where the possible risk of thrombosis was attributed to the anti-angiogenic agent [3]. Our patient did not receive bevacizumab therapy.…”
Section: Discussionmentioning
confidence: 77%
“…CVST is an uncommon type of VTE [1][2][3][4]. The incidence of CVST was about 0.3-4% in cancer patients, with cancer increasing risk for CVST roughly 5-fold [5,7].…”
Section: Discussionmentioning
confidence: 99%
See 3 more Smart Citations